Coprevalence of type 2 diabetes mellitus and tuberculosis in low‐income and middle‐income countries: A systematic review. Issue 1 (25th September 2018)

• Record Type: Journal Article
• Authors: McMurry, Hannah Stowe; Mendenhall, Emily; Rajendrakumar, Aravind; Nambiar, Lavanya; Satyanarayana, Srinath; Shivashankar, Roopa
• Is Part Of: Diabetes/metabolism research and reviews. Volume 35:Issue 1(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-09-25
• Subjects: coprevalence -- low‐income and middle‐income countries -- tuberculosis -- type 2 diabetes; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.642
• DOI: 10.1002/dmrr.3066
• Languages: English
• ISSNs: 1520-7552

Abstract

Summary: Increasing coprevalence of diabetes mellitus (DM) and tuberculosis (TB) in low‐income and middle‐income countries (LMICs) indicates a rising threat to the decades of progress made against TB and requires global attention. This systematic review provides a summary of type 2 diabetes and tuberculosis coprevalence in various LMICs. We searched PubMed, Ovid Medline, Embase, and PsychINFO databases for studies that provided estimates of TB‐DM coprevalence in LMICs published between 1990 and 2016. Studies that were non‐English and exclusively conducted in multidrug resistant‐tuberculosis or type 1 diabetes and inpatient settings were excluded. We reviewed 84 studies from 31 countries. There were huge diversity of study designs and diagnostic methods used to estimate coprevalence, and this precluded pooling of the results. Most studies (n = 78) were from small, localized settings. The DM prevalence among TB patients in various LMICs varied from 1.8% to 45%, with the majority (n = 44) between 10% and 30%. The TB prevalence among people with DM ranged from 0.1% to 6.0% with most studies (n = 9) reporting prevalences less than 2%. Coprevalence of TB‐DM was higher than general population prevalence of either diseases in these countries. This study underscores the need for intervention and more focused research on TB DM bidirectional screening programs in low‐income and middle‐income countries as well as integrated chronic disease management.